Artixio

Regulatory Affairs Consulting for Life Sciences in Japan

Expert Regulatory Affairs Consulting for Life Sciences Industries in Japan, Supporting Market Entry and Compliance

Regulatory Affairs Services in Japan

At Artixio, we assist life sciences businesses in meeting Japan’s regulatory requirements. From product development to post-market support, our team works closely with you to ensure your products comply with local regulations.
We aim to make the approval process clear and efficient, helping your products reach the market confidently. With our expertise, you’ll receive guidance throughout the process, giving you the support you need to succeed in Japan.
Industry Regulatory Body
Pharmaceuticals & Medical Devices Pharmaceuticals and Medical Devices Agency (PMDA) Ministry of Health, Labour, and Welfare (MHLW)
Cosmetics Ministry of Health, Labour, and Welfare (MHLW)
Nutrition Products Consumer Affairs Agency (CAA)
Veterinary Products Animal Health and Food Safety Department (MHLW)

Regulatory Affairs Lifecycle in Japan

Gather all necessary documents and data (clinical trials, product details, etc.) for submission.
Submit the required information to the appropriate regulatory authority (e.g., PMDA, MHLW).
The regulatory authority assesses your product's safety, effectiveness, and compliance with local standards.
Monitor the product's performance and safety once it’s on the market.
Regularly review and update approvals to maintain ongoing market access and compliance.

Why Artixio for Japan’s regulatory affairs

FAQs

What are the main regulatory bodies in Japan?
The Pharmaceuticals and Medical Devices Agency (PMDA) and the Ministry of Health, Labour, and Welfare (MHLW) are the key authorities responsible for product approvals in Japan. For other products, such as food and cosmetics, the Consumer Affairs Agency (CAA) plays an important role.
You will need to submit a variety of documentation, including clinical data, safety profiles, manufacturing details, and product labeling, depending on the product type. It’s important to ensure that all documents meet Japanese standards.
Once approved, your product will be registered, and you can begin market distribution. However, ongoing post-market surveillance and reporting are required to monitor product safety and effectiveness.
Yes, post-market surveillance is mandatory in Japan, and products must undergo periodic inspections and adverse event reporting. Continuous monitoring is essential to maintain compliance.

Still Have Questions ?

Get expert answers tailored to your needs.

Industries We Serve in the Japan

Pharmaceuticals

MedTech

Cosmetics

Nutrition

Biologics

Veterinary

Expert Regulatory Services To Streamline Compliance

Regulatory Intelligence & Strategy
Medical & Technical Writing
Publishing & Submission
Product Registration
Investigation New Drug Application (IND)
New Drug Application (NDA)
Post Approval Lifecycle Maintenance
Artwork and Label Review
Ad Promo Review

Regulatory Affairs Across Multiple Countries

India

Singapore

Mexico

Brazil

Vietnam

Malaysia

Argentina

Colombia

Taiwan

China

European

Thailand

Indonesia

Philippines

USA

Japan

Qatar

South Korea

Insights from Artixio - Tips & Articles

Pharma Manufacturing Booms in Hidalgo, Mexico

Pharma Manufacturing Booms in

Hildalgo had good pharmaceutical infrastructure and supply chain capabilities, but with no foreign investment...

May 2, 2025
UK Releases Amendment & Guidance on Regulations in 2024 for Medical Devices (Post-market Surveillance Requirements)

UK Releases Amendment &

In January 2025, MHRA UK released guidance on implementation of amendments to Medical Devices...

April 23, 2025
Artixio Announces Grant for Early Stage Medtech Innovators as Part of MedTech InnovateIO Initiative

Artixio Announces Grant for

HYDERABAD, India - March 27, 2024 - Artixio, a leading compliance and commercial consulting...

April 16, 2025